Dyslipidemia

Renova Therapeutics is planning a 536-patient phase 3 trial, FLOURISH, to begin in early 2018.

Kevin Maki, PhD, discussed the current state of lipid care in the United States.

OZEMPIC, a GLP-1 receptor agonist, was tested in 2-year cardiovascular outcome trials.

The smart strap is the first medical accessory for a smartwatch to receive FDA approval.

ODYSSEY DM-DYSLIPIDEMIA is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.

Praluent can help patients with clinical ASCVD or HeFH

Pitavastatin is superior to pravastatin in reducing LDL in patients with HIV.

Certain conditions are linked to multiple sclerosis disease progression.

Breakthrough status for a new drug to treat familial hypercholesterolemia.

Steven Nissen, MD, says that heart attacks in fit people are not unusual.

Systemic atherosclerosis causes peripheral artery disease, and these patients are at risk of cardiovascular death and stroke.

Do patients diagnosed with anxiety disorder experience a greater burden of metabolic disorders such as diabetes and hyperlipidemia?

Metformin and pioglitazone could be beneficial for patients with multiple sclerosis and metabolic syndrome, researchers in Argentina report.

From cardiologists to physical therapists to nurses there is a team approach needed to provide cardiac patients the care they need for treatment. Keeping that care going even after a cardiac event has passed has been a growing focus of the field in recent years.

It has become unnecessary for dermatologists to request monthly lab tests for patients administered standard doses of isotretinoin for the treatment of severe acne.